Financial Data and Key Metrics Changes - Invivyd's net revenues for Q4 2025 increased by 31% compared to Q3 2025 and by 25% compared to Q4 2024, totaling $53.4 million for the full year 2025 [26] - The company ended the year with $226.7 million in cash and cash equivalents, positioning it well for upcoming pivotal data for VYD2311 in mid-2026 [26] Business Line Data and Key Metrics Changes - The commercial work with PEMGARDA showed growth in Q4, establishing a foundation for broader commercialization of VYD2311 if approved [5] - The company reported a high reorder rate of 77% for PEMGARDA, indicating strong ongoing demand [24] Market Data and Key Metrics Changes - There is a growing recognition of monoclonal antibodies in the medical community, with leading organizations recommending their use for high-risk patients [22] - The company has secured over 15,000 contracted GPO sites, significantly expanding its commercial footprint [24] Company Strategy and Development Direction - Invivyd aims to redefine COVID prevention with its next-generation monoclonal antibody, moving towards a vaccine alternative strategy [25] - The company is focusing on expanding its portfolio to include treatments for other infectious diseases, such as RSV and measles, indicating a broader strategic vision [8][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for VYD2311 to provide effective protection against symptomatic COVID-19 [18] - The company is optimistic about the speed of study recruitment and the potential for robust assessment of VYD2311's effectiveness [20] Other Important Information - Invivyd is conducting its third randomized placebo-controlled trial for a COVID monoclonal antibody, which is designed to adapt to virus evolution [14] - The company is exploring the use of monoclonal antibodies for long COVID and post-vaccination syndrome, highlighting its commitment to addressing unmet medical needs [7] Q&A Session Summary Question: Can you elaborate on the potential trial resizing decision in the DECLARATION program? - Management indicated that the resizing decision would depend on the expected vaccine efficacy and the number of events accumulated, with a potential upsizing target of approximately 30% [29][30] Question: Are secondary endpoints being collected in the trial? - Management confirmed that various interactions, including healthcare utilization, would be recorded, but cautioned against expecting meaningful powering of low-frequency clinical events [34][35] Question: What is the envisioned use case for the measles antibody program? - Management highlighted potential use cases for outbreak prophylaxis and pediatric bridge therapy, emphasizing the antibody's design to address specific medical needs [37][41] Question: How is the DECLARATION study configured to target areas with high COVID rates? - Management explained that the study sites are strategically located in areas with community COVID attack rates, utilizing various data sources to inform site selection [46][48] Question: What is the approach to monitoring myocarditis in the study? - Management stated that the monitoring would primarily focus on clinical myocarditis events, with the possibility of further exploration if such events occur [50][51] Question: How does Invivyd plan to compete in the RSV antibody market? - Management expressed confidence in their antibody's properties and the potential to address evolutionary drift, positioning it as a competitive option in the RSV market [56][58]

Financial Data and Key Metrics Changes - Invivyd's net revenues for Q4 2025 increased by 31% compared to Q3 2025 and by 25% compared to Q4 2024, totaling $53.4 million for the full year 2025 [25] - The company ended the year with $226.7 million in cash and cash equivalents, positioning it well for upcoming pivotal data for VYD2311 in mid-2026 [25] Business Line Data and Key Metrics Changes - The commercial activities with PEMGARDA showed growth in Q4, establishing a foundation for broader commercialization of VYD2311 if approved [5] - The company reported a high reorder rate of 77% for PEMGARDA, indicating strong ongoing demand [23] Market Data and Key Metrics Changes - There is a growing recognition among healthcare professionals of the importance of monoclonal antibodies for COVID prevention, as reflected in clinical guidelines from leading organizations [22] - Invivyd has secured over 15,000 contracted GPO sites, significantly expanding its commercial footprint [23] Company Strategy and Development Direction - Invivyd aims to redefine COVID prevention with its next-generation monoclonal antibody, moving towards a vaccine alternative strategy [24] - The company is focusing on expanding its portfolio to include treatments for other infectious diseases, such as RSV and measles, which could enhance its market presence [8][41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing clinical trials and the potential for VYD2311 to provide effective protection against symptomatic COVID-19 [20] - The company is closely monitoring the evolving COVID landscape and is prepared to adapt its strategies based on community infection rates [46] Other Important Information - The DECLARATION clinical trial for VYD2311 has reached its target enrollment, with the potential for modest over-enrollment [16] - The company is excited about the potential of its RSV antibody, which is designed to compete with existing treatments in the market [54] Q&A Session Summary Question: Can you elaborate on the potential trial resizing decision in the DECLARATION program? - Management indicated that resizing would depend on the expected vaccine efficacy and the number of events accumulated, with a potential upsizing target of approximately 30% [30][31] Question: Are secondary endpoints being collected in the DECLARATION study? - Management confirmed that various interactions, including healthcare utilization, will be recorded, although they cautioned against expecting meaningful powering for low-frequency clinical events [33][36] Question: What is the envisioned use case for the measles antibody program? - Management highlighted potential use cases including outbreak prophylaxis and pediatric bridge therapy, emphasizing the need for innovative solutions in pediatric care [37][39] Question: How is the DECLARATION study being configured to target areas with high COVID rates? - Management explained that they are utilizing community data to place study sites in areas with higher COVID attack rates, although they acknowledged the challenges of rapidly changing conditions [46] Question: What is the monitoring plan for myocarditis in the LIBERTY study? - Management stated that the monitoring will primarily be a yes/no exercise for overt myocarditis, with the possibility of further exploration if events occur [48]